Press Releases
Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational Highlights
Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol Levels
Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic Using Yeast Beta Glucan Processed with Pressurized Gas eXpanded Technology (PGX-YBG)
Ceapro Inc. to Present at the Virtual Investor Roundtable Event
Ceapro Inc. to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Ceapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational Highlights
Ceapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation for Beta Glucan and Avenanthramides
Ceapro Inc. Expands Collaboration with Montreal Heart Institute (MHI) with New Clinical Study Evaluating Flagship Product, Avenanthramide
Ceapro Announces Results of 2021 Shareholders’ Meeting
